Previous 10 | Next 10 |
Summary A Psychedelic drug company shakeout appears to be happening, companies are closing doors and others are running on fumes. Cybin has made moves to take advantage of the situation and strengthen its cash position. Cybin is behind the leaders with its drug program but mig...
For decades, LSD has been one of the most popular recreational psychedelics despite being outlawed by the federal and state governments. In recent years, however, more and more people have begun using psychedelics such as LSD medicinally as an increasing number of studies have shown that ...
United Kingdom-based psychedelics company Compass Pathways (Nasdaq: CMPS) posted a net loss of $18.4 million for the third quarter of 2022, but company leadership insisted in a press release that the business is well-positioned to capitalize on the growing psilocybin industry. ...
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q3 2022 Earnings Call Nov 03, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript
COMPASS Pathways ADS press release ( NASDAQ: CMPS ): Q3 GAAP EPS of -$0.43 beats by $0.22 . Cash and cash equivalents were $173.1 million as of 30 September 2022, compared with $273.2 million as of 31 December 2021. Shares +1.53% PM. For further details s...
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2022 a...
After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant depression (TRD) were in remission at week 3 Sustained response seen through week 12 in twice the number of TRD patients that received 25mg dose vs 1mg ...
COMPASS Pathways ADS ( NASDAQ: CMPS ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.64 (-68.4% Y/Y) Over the last 1 year, CMPS has beaten EPS estimates 50% of the time and has beaten re...
Psychedelic companies have appeared to be pretty sensitive to stock market changes, reacting to ups and downs on the Nasdaq and NYSE like any other company in a nascent industry would. But that sensitivity seems to be lessening for some psychedelic companies, which have maintained...
Psychedelics have long been heralded for their numerous benefits , with recent studies showing that these substances may be useful in the treatment of various mental health conditions. These benefits have increased interest in these substances, with... Read more » About Psyche...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...